Researchers have made more advancements in multiple sclerosis in the last five years than in the previous 70 years. Knowing ...

The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

Mikael Simons, MD, a neurologist and researcher at Technical University Munich and the Centre for Neurodegenerative Diseases ...

Migraine may be a symptom of prodromal multiple sclerosis (MS), as the risk for migraine gradually increased closer to the ...

Patients should stop taking glatiramer acetate and seek immediate medical attention by going to an emergency room or calling ...

Trouble sleeping is common in other neurodegenerative diseases, but past research has only suggested that it occurs in ...

is the most common type of multiple sclerosis (MS), making up about 85% of diagnoses. RRMS involves periods known as relapses, during which symptoms worsen, followed by periods of symptom ...

Earlier studies indicated that COVID infection might cause MS symptoms to worsen, particularly if the symptoms coincide with those associated with long COVID. For this new study, researchers tracked ...

The FDA reported that six patients died after being injected with Teva’s Copaxone or Sandoz’s Glatopa. The US Food and Drug ...